Logo

XTLB

XTL Biopharmaceuticals Ltd.

XTLB

XTL Biopharmaceuticals Ltd. • NASDAQ
$0.83 ▲ 4.40% (+0.04)
Market Cap $4.52 M
52w High $2.57
52w Low $0.77
Dividend Yield 0%
P/E -2.77
Volume 19.85K
Outstanding Shares 5.45M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $289K ▲ $769K ▼ $-255K ▲ -88.235% ▲ $-0.04 ▲ $-429.25K ▼
Q3-2024 $162K ▲ $926K ▲ $-553K ▲ -341.358% ▼ $-0.1 ▲ $-156K ▲
Q2-2024 $0 $421K ▲ $-704K ▼ 0% $-0.13 ▼ $-691K ▼
Q1-2024 $0 $175K ▼ $485K ▲ 0% $0.09 ▲ $485K ▲
Q4-2023 $0 $200K $-284K 0% $-0.05 $-284K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $1.143M ▼ $8.55M ▼ $3.115M ▼ $5.435M ▼
Q3-2024 $1.72M ▲ $9.28M ▲ $3.563M ▲ $5.717M ▲
Q2-2024 $1.586M ▼ $2.398M ▼ $165K ▼ $2.233M ▼
Q1-2024 $2.339M ▲ $2.928M ▲ $223K ▲ $2.705M ▲
Q4-2023 $2.006M $2.426M $206K $2.22M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $-255K ▲ $0 $0 $0 $0 $0
Q3-2024 $-553K ▲ $0 $0 $0 $0 $0
Q2-2024 $-704K ▼ $0 $0 $0 $0 $0
Q1-2024 $485K ▲ $0 $0 $0 $0 $0
Q4-2023 $-284K $0 $0 $0 $0 $0

Five-Year Company Overview

Income Statement

Income Statement The income statement reflects a tiny, early‑stage business with very limited historical revenue and a pattern of losses. The company has shifted from long-horizon drug development to a more near-term, service-based data business, but expenses still appear to outweigh income. Profitability is not established, and the path to consistent earnings depends heavily on scaling The Social Proxy, managing operating costs, and converting its technology edge into recurring, high-quality revenue. Overall, results so far look like a company still in investment and build-out mode rather than one generating steady profits.

Balance Sheet

Balance Sheet The balance sheet looks very thin and fragile, with only a small asset base and minimal equity. There is no meaningful reported debt, but that is mostly because the company is very small, not because it is highly cash-rich. This profile suggests a business that likely relies on periodic capital raises to fund operations rather than on internally generated resources. Any downturn in funding conditions or delays in revenue growth could put pressure on its financial flexibility, so its capital structure is simple but not especially robust.

Cash Flow

Cash Flow Reported cash flow data are sparse, but the overall picture is of a company that consumes cash to fund operations and growth instead of generating it. Capital spending needs appear modest, which fits a software-and-infrastructure model, but ongoing investment in hardware, network capacity, and product development still requires funding. With limited internal cash generation, the company’s ability to continue investing will likely depend on external financing and how quickly it can grow paying customers. Monitoring cash burn and future fundraising will be important, as small changes in either can materially affect runway.

Competitive Edge

Competitive Edge Competitively, XTL has effectively stepped out of the crowded biopharma race and into an equally competitive, fast-moving web data and proxy market. The Social Proxy’s claimed advantages—owned 4G/5G infrastructure, high speeds, an “ethical” sourcing model, and simple pricing—give it a differentiated story in a niche focused on social media automation and large-scale web scraping. However, it is going up against larger, better-capitalized incumbents that already serve many of the same use cases. The company’s position will depend on its ability to keep its technology edge, win trusted relationships with compliance-sensitive clients, and scale up without eroding service quality or margins.

Innovation and R&D

Innovation and R&D Innovation has shifted from long, regulated clinical trials to faster-cycle technology development. On the new side, the company is innovating in high-speed mobile proxy hardware, network architecture, and a data-extraction platform aimed at feeding AI and business intelligence. This can support rapid iteration and new features, but it also requires constant investment to stay ahead of competitors. On the old side, the company still owns biopharmaceutical assets, including a late-stage-ready Lupus candidate, but these programs appear sidelined and underfunded. If reactivated, licensed, or sold, they could add optionality, but there is substantial uncertainty given the lack of recent progress or disclosure.

Summary

XTL Biopharmaceuticals is now essentially a small web data and AI infrastructure company with legacy drug assets in the background. Financially, it looks like an early-stage, loss-making business with a light balance sheet, limited reported revenues, and dependence on external capital to support growth. Strategically, the acquisition of The Social Proxy has given it a clear new focus in a high-growth but intensely competitive market where speed, reliability, and ethical data sourcing matter. The main opportunities lie in scaling this new platform, deepening its technology moat, and potentially unlocking value from the dormant biopharma portfolio. The main risks center on execution in a crowded tech niche, sustaining funding, navigating evolving data-privacy expectations, and the possibility that the legacy drug pipeline remains stranded rather than monetized. Overall uncertainty is high, and the story is still very much in transition.